F10 and Huntington disease: FDA approval was allegedly primarily based on PK data originating from a small study by Wang et al.38in which eight HD patients and eight healthy subjects were treated with apixaban 5 mg resulting in comparable maximum blood concentrations and anti‐factor Xa activity.34, 38